Who is the new Chief Medical Officer at Parabilis Medicines?

Parabilis Medicines named Fawzi Benzaghou Chief Medical Officer, announced September 3, 2025.

Which similar companies made leadership changes around the same time?

Acadia Pharmaceuticals (August 26, 2025), Cantargia AB (August 18, 2025), MacroGenics (August 13, 2025) and Biofrontera (August 11, 2025) also announced leadership changes within 45 days of Parabilis Medicines.

Parabilis Medicines Appoints Fawzi Benzaghou as Chief Medical Officer

PUBLIC · PBLSSep 03, 2025

Position

Chief Medical Officer

Company

Parabilis Medicines

Fawzi Benzaghou

fbenzaghou@parabilismed.com

CambridgeBiotechnologyHealthcareHealth CareTherapeuticsPharmaceuticalBiopharma

Description

Parabilis Medicines has announced the appointment of Fawzi Benzaghou, M.D., as the company’s Chief Medical Officer. Dr. Benzaghou will oversee the clinical strategy and operations, advancing a pipeline of promising investigational therapies for oncology.

Quick answer

Parabilis Medicines Appoints Fawzi Benzaghou as Chief Medical Officer (September 3, 2025). Parabilis Medicines is based in Cambridge, Massachusetts, United States.

Who is the new Chief Medical Officer at Parabilis Medicines?: Parabilis Medicines named Fawzi Benzaghou Chief Medical Officer, announced September 3, 2025.
What did Parabilis Medicines announce on September 3, 2025?: Parabilis Medicines has announced the appointment of Fawzi Benzaghou, M.D., as the company’s Chief Medical Officer. Dr. Benzaghou will oversee the clinical strategy and operations, advancing a pipeline of promising investigational therapies for oncology.
What does Parabilis Medicines do?: Parabilis Medicines™ is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for people living with cancer.
Where is Parabilis Medicines based?: Parabilis Medicines is based in Cambridge, Massachusetts, United States.
Which similar companies made leadership changes around the same time?: Acadia Pharmaceuticals (August 26, 2025), Cantargia AB (August 18, 2025), MacroGenics (August 13, 2025) and Biofrontera (August 11, 2025) also announced leadership changes within 45 days of Parabilis Medicines.

Source: Fundz verified event record.

Other recent leadership changes in Healthcare and Therapeutics

Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.

Acadia Pharmaceuticals Appoints Konstantina Katcheves as Chief Business and Strategy Officer (August 26, 2025)
Cantargia Appoints Dr Hilde Steineger as Chief Executive Officer (August 18, 2025)
MacroGenics Appoints Eric Risser as President and Chief Executive Officer (August 13, 2025)
Biofrontera Inc. Appoints George Jones as Chief Commercial Officer (August 11, 2025)
Nuvalent Promotes Jason Waters to Senior Vice President, Commercial (August 7, 2025)
Atossa Therapeutics Appoints Mark Daniel as Chief Financial Officer (October 14, 2025)

Who to call at Parabilis Medicines, and when

A new leader at Parabilis Medicines brings new priorities and often new vendors. The first weeks are when they listen.

An alert the day Parabilis Medicines raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Parabilis Medicines, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Parabilis Medicines. With Fundz connected, it knows.

Watch Fundz in

See plan options

Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Parabilis Medicines

Location

30 Acorn Park Drive

Cambridge, Massachusetts, United States

About

Parabilis Medicines™ is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for people living with cancer. Through our pioneering Helicon™ discovery platform, Parabilis is engineering precisely-tuned, stabilized helical peptide therapeutics that have the potential to unlock a large number of traditionally undruggable targets. FOG-001, our first-in-class TCF-blocking β-catenin inhibitor and lead clinical program, is being evaluated in a Phase 1/2 study for patients with colorectal cancer and other solid tumors and is proof of the applicability of our platform to address undruggable intracellular protein-protein targets. We are additionally advancing a pipeline of other first-in-class programs that target proteins known to be relevant to numerous cancers, but considered intractable with traditional drug modalities. The versatility of the Helicon approach allows for the discovery of multiple targeting mechanisms, including functional protein-protein interaction inhibitors, bifunctional degraders, and radioligand therapeutics. We are headquartered in Cambridge, Mass., and are well-capitalized, with more than $500 million raised to date from leading life sciences investors.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Parabilis Medicines changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Book a demo Explore plans